George Medicines Expands Global Commercialization Of GMRx2 With Exclusive Licensing Deal With Biolab Farmacêutica In Brazil

George Medicines, a late-stage biopharmaceutical company focused on addressing unmet needs in cardiometabolic disease, announced an exclusive licensing and supply agreement with Biolab Farmacêutica, one of Brazil’s largest pharmaceutical companies. Under this agreement, Biolab will have exclusive rights to seek regulatory approval for and commercialize GMRx2 in Brazil. GMRx2 is an innovative single-pill combination of three medicines — telmisartan, amlodipine, and indapamide developed in three doses, including two lower doses than those currently available in other single-pill combinations for hypertension.

The multi-mechanism formulation of GMRx2 is designed to provide the blood pressure-lowering benefits of a triple combination therapy early in the treatment process, while maintaining the safety profile of established antihypertensive medications. Since most patients with hypertension require two or more medications to control their blood pressure, clinical guidelines support the early use of single-pill combination therapies for improved outcomes.

Mark Mallon, Chief Executive Officer of George Medicines, said in a statement, “This partnership in Brazil further strengthens our global commercial strategy for GMRx2 and follows on swiftly from the product’s regulatory approval in the US and licensing agreements covering the US, Canada, Mexico, Colombia and Central America markets. The clinically-proven efficacy of this triple combination product, with its multiple dosing options including two doses that are lower than those currently available in single pill combinations, coupled with its established safety profile, has the potential to address key challenges in current hypertension treatment approaches. Through our partnership with Biolab we have an opportunity with GMRx2 to meaningfully advance cardiovascular care in Brazil.”

Fabio Amorosino, Chief Executive Officer of Biolab Farmacêutica, mentioned, “The partnership with George Medicines for the exclusive commercialization of GMRx2 reinforces Biolab’s strategic presence in the cardiovascular segment. The medication, which will undergo regulatory approval in Brazil, represents a significant innovation in hypertension treatment. With a solid infrastructure and strong medical presence, we are well prepared to expand access to effective and safe healthcare solutions for the population.” 

As part of the agreement, George Medicines will receive an upfront licensing fee, potential regulatory and commercial milestone payments, and a future recurring revenue stream through a stepped royalty on GMRx2 sales in Brazil. Biolab Farmacêutica will be responsible for obtaining regulatory approval in the country and for commercializing the medicine, with support from George Medicines, which will continue supplying GMRx2.

This agreement represents George Medicines’ third licensing and supply deal for GMRx2. Earlier agreements include a partnership with Bausch Health in January 2025, granting rights in Canada, Mexico, Colombia, and Central America, and with Azurity Pharmaceuticals in July 2025 for exclusive rights in the United States. George Medicines anticipates further collaborations to expand global access to this important therapy.

George Medicines is an independent spin-out from The George Institute for Global Health, a leading medical research institute focused on addressing global health inequities. The company is supported by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm.